Truncated human leptin (delta133) associated with extreme obesity undergoes proteasomal degradation after defective intracellular transport.
We recently described a homozygous frameshift mutation in the human leptin (ob) gene associated with undetectable serum leptin and extreme obesity in two individuals. This represented the first identified genetic cause of morbid obesity in humans. Preliminary data suggested a defect in the secretion of this truncated (delta133) mutant leptin. In the present investigation, we have examined the mechanisms underlying the defective secretion of the delta133 leptin in transient transfection studies in Chinese hamster ovary and monkey kidney epithelium cells. Consistent with our previous observations, only immunoreactive wild-type (wt) leptin was secreted. In pulse chase experiments, intracellular wt leptin levels decreased, concomitant with secretion into the medium. In contrast, though immunoreactive delta133 leptin disappeared from cell lysates with kinetics similar to those of wt leptin (half-life, 45 min), it was not detected in the medium. Inhibition of the proteasome, using the inhibitor clastolactacystin beta-lactone, led to a significant increase in the intracellular levels of delta133 leptin, indicating a role for the proteasome in the degradation pathway. Although intracellular immunoprecipitated wt and delta133 leptin levels were comparable, analysis of total cell lysates revealed a 7-fold increase in total intracellular delta133 leptin, compared with wt leptin. Size-exclusion membrane filtration demonstrated that intracellular delta133 leptin accumulated in an aggregated form, presumably as a result of misfolding in the endoplasmic reticulum. Consistent with this, an endoplasmic reticulum-like localization for delta133 leptin was detected by immunofluorescence microscopy. In conclusion, the delta133 mutant leptin is not secreted but accumulates intracellularly, as a consequence of misfolding/aggregation, and is subsequently degraded by the proteasome. These studies further define the genotype/phenotype correlation in this paradigmatic case of human leptin deficiency.
Rau
H
H
Department of Medicine, University of Cambridge, Addenbrooke's Hospital, United Kingdom.
Reaves
B J
BJ
O'Rahilly
S
S
Whitehead
J P
JP
D000818:Animals; D001692:Biological Transport; D015153:Blotting, Western; D016466:CHO Cells; D019556:COS Cells; D006224:Cricetinae; D003546:Cysteine Endopeptidases / Q000378:metabolism*; D005455:Fluorescent Antibody Technique; D016368:Frameshift Mutation; D006801:Humans; D007163:Immunosorbent Techniques; D020738:Leptin; D008856:Microscopy, Fluorescence; D009097:Multienzyme Complexes / Q000378:metabolism*; D009767:Obesity, Morbid / Q000235:genetics*; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000235:genetics* / Q000378:metabolism; D014162:Transfection
D020738:Leptin; D009097:Multienzyme Complexes; D011506:Proteins; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex